<DOC>
	<DOCNO>NCT00667563</DOCNO>
	<brief_summary>RATIONALE : Vaccines make virus protein may help body build effective immune response prevent cervical cancer . PURPOSE : This pilot study look side effect human papillomavirus vaccine well work prevent cervical cancer woman India HIV-1 infection .</brief_summary>
	<brief_title>Vaccine Therapy Preventing HPV HIV-Positive Women India</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety Gardasil® quadrivalent human papillomavirus ( HPV ) ( type 6 , 11 , 16,18 ) virus-like-particle vaccine v without prior exposure one HPV type vaccine HIV-positive woman Chennai , India . - Determine effect vaccine HIV viral load CD4+/CD8+ level patient . - Determine proportion patient respond serologically HPV vaccine kinetics response . Secondary - Determine prevalence incidence cervical intraepithelial neoplasia patient . - Determine spectrum cervical HPV type patient baseline , 9 month , 1 year vaccination . OUTLINE : This multicenter study . Patients receive quadrivalent human papillomavirus ( HPV ) ( type 6 , 11 , 16 , 18 ) recombinant vaccine intramuscularly day 0 week 8 24 . Patients undergo cervical cell , buccal cell , blood sample collection baseline periodically vaccination immunologic virologic study . Cervical cytology specimen examine polymerase chain reaction detect HPV 6 , 11 , 16 , 18 DNA , well 35 HPV type . Blood sample analyze CD4+/CD8+ cell count , plasma HIV-1 RNA level , serum HPV antibody titer HPV type 6 , 11 , 16 , 18 . Some plasma sample store future HPV pseudovirion neutralization assay . After completion study therapy , patient follow periodically 12 month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : HIV1 infection , document licensed ELISA test kit confirm western blot study entry HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test Meets 1 follow criterion : Nadir CD4 level ≤ 350 cells/mm³ receive highly active antiretroviral therapy ( HAART ) least 6 month study entry Nadir CD4 level &gt; 350 cells/mm³ receive HAART time study entry No known history highgrade CIN cervical cancer PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % ANC &gt; 750 cells/mm³ Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 3 time upper limit normal ( ULN ) AST ALT ≤ 3.0 time ULN Conjugated ( direct ) bilirubin ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active drug alcohol use dependence would interfere adherence study requirement , opinion site Investigator No serious illness require systemic treatment and/or hospitalization within past 45 day No allergy yeast component quadrivalent human papillomavirus ( type 6 , 11 , 16 , 18 ) recombinant vaccine PRIOR CONCURRENT THERAPY : See Disease Characteristics More 45 day since prior systemic antineoplastic immunomodulatory treatment , systemic corticosteroid , investigational vaccine , interleukin , interferon , growth factor , intravenous immunoglobulin Routine standard care , include hepatitis B , influenza , tetanus vaccine allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>human papilloma virus infection</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>cervical intraepithelial neoplasia</keyword>
	<keyword>HIV infection</keyword>
</DOC>